MyT1L-AS1: A Potential Drug Target and Biomarker (G730811)

Target Name: MYT1L-AS1

NCBI ID: G730811

MYT1L-AS1

Other Name(s): MYT1L antisense RNA 1

MyT1L-AS1: A Potential Drug Target and Biomarker

MyT1L-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure, expressed in a pre-mRNA format, is composed of a single exon surrounded by a UTR-like region and a repetitive sequence of nontranscribing RNA (NTR) domains. This RNA molecule has been shown to play a critical role in the regulation of cell growth, apoptosis, and transcriptional regulation in various organisms, including humans.

MYT1L-AS1 functions as a negative regulator of the growth factor-induced G1 cell cycle, leading to the inhibition of cell proliferation and the G2/M phase transition. This RNA molecule has been shown to target the Ku70 gene, which encodes the nuclear protein Ku70. Ku70 is a key regulator of the G1 phase, and its expression is known to be regulated by various factors, including the growth factors IP3 and WF1.

MYT1L-AS1 has also been shown to play a role in the regulation of cell apoptosis. In cancer cells, the indomethacin-insensitive G1 cell cycle is a significant factor in the survival and proliferation of these cells. The G1/S transition is a critical event in the cell cycle, and the regulation of this transition is crucial for the development and progression of cancer. The Ku70 gene has been shown to be involved in the regulation of the G1/S transition by promoting the expression of the pro- apoptotic gene p53.

MYT1L-AS1 has also been shown to play a role in the regulation of gene expression in various organisms, including humans. For instance, studies have shown thatMYT1L-AS1 can interact with various transcription factors, including nuclear factor E2F1, to regulate the expression of target genes. This interaction between MYT1L-AS1 and transcription factors highlights the potential role of this RNA molecule in the regulation of gene expression.

In addition to its potential drug target and biomarker properties, MYT1L-AS1 has also been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion. These functions are critical for the development of cancer stem cells, which are highly resistant to chemotherapy and have a poor prognosis. The regulation of cellular processes by MYT1L-AS1 may have implications for the development of cancer therapies that target these processes.

In conclusion, MYT1L-AS1 is a highly promising drug target and biomarker with various functions, including the regulation of cell growth, apoptosis, and transcriptional regulation. The unique structure of this RNA molecule, expressed in a pre-mRNA format, makes it a unique candidate for drug development. Further studies are needed to fully understand the mechanisms of its function and its potential as a drug target.

Protein Name: MYT1L Antisense RNA 1

The "MYT1L-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYT1L-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets